Presenting
Coro Energy
is a South East Asian focused energy company with a regional strategy of investing in low carbon energy assets including renewables and energy storage, supported by an existing platform of gas assets.
Destiny Pharma
Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Destiny Pharmas vision is of an expanding range of new antimicrobial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due to the existence or threat of antibiotic resistance.
The proprietary, new antimicrobial drug platform at Destiny Pharma, the XF Drug Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.
Serica Energy
Serica Energy (AIM:SQZ) is a British independent oil and gas exploration and production company with a portfolio of North Sea assets, with a balance of gas and oil production. The Company is responsible for about 5% of the natural gas produced in the UK, a key element in the UK's energy transition. Serica’s production is materially cash-generative, and the Company has paid dividends of over £200 million since distributions began in 2020. Serica has a two-pronged strategy for growth comprising investment in its existing portfolio and M&A.
VolitionRx
VolitionRX is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, VolitionRX products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
VolitionRX research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
